1. Home
  2. GLYC

as 05-20-2024 1:32pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

Founded: 2003 Country:
United States
United States
Employees: N/A City: ROCKVILLE
Market Cap: 16.9M IPO Year: 2014
Target Price: $12.00 AVG Volume (30 days): 1.5M
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.58 EPS Growth: N/A
52 Week Low/High: $0.26 - $3.53 Next Earning Date: 05-09-2024
Revenue: $10,000 Revenue Growth: -86.67%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: